MeiraGTx Holdings plc — Q1 2019 Form 10-Q
Business context and reporting period
Clinical-stage gene therapy company; unaudited results cover the three months ended March 31, 2019, compared with Q1 2018. The company reported five clinical programs and additional preclinical and research programs, with no approved products and no product-sale revenue.
Financial performance and position
| Metric | Q1 2019 | Q1 2018 / prior date |
|---|---|---|
| License revenue | $0.8 million | None |
| Operating expenses | $21.5 million | $18.0 million |
| Operating loss | $20.7 million | $18.0 million |
| Net loss | $18.0 million | $16.4 million |
| Adjusted net loss per share | $0.62 | $1.91 |
| Cash and cash equivalents, March 31 | $227.3 million | $68.1 million at December 31, 2018 |
| Operating cash flow | $82.2 million | $(17.4) million |
| Capital expenditures | $1.1 million | $1.2 million |
| Financing cash flow | $77.6 million | $42.4 million |
| Total liabilities | $113.4 million | $15.8 million at December 31, 2018 |
Q1 2019 license revenue was amortization of Janssen’s $100 million upfront payment; $99.2 million remained deferred at quarter-end. Janssen research and development reimbursements of $1.0 million were recorded as an offset to R&D expense, not as revenue. No product gross margin was reported. The company had no debt outstanding other than ordinary-course payables, accruals and lease obligations; lease obligations were $3.6 million operating and $0.03 million finance. Current assets were $231.2 million and current liabilities $33.2 million.
Material changes versus Q1 2018
- R&D expense rose $6.0 million to $13.0 million, primarily reflecting approximately $4.0 million in UCL license amendment costs and higher manufacturing and clinical costs; Janssen funding partially offset costs.
- General and administrative expense declined $2.6 million to $8.5 million, mainly due to lower payroll and share-based compensation.
- Net loss widened by $1.6 million. A larger foreign-currency gain partly offset the higher operating loss; the prior-year period also included a warrant fair-value gain.
- Operating cash flow turned positive largely because of the Janssen upfront payment, which is deferred revenue and does not represent recurring operating cash generation. Financing cash flow included net proceeds of $77.6 million from an $80 million private placement.
- Ordinary shares outstanding increased to 33.3 million from 27.4 million at year-end 2018, reflecting the placement and shares issued under a UCL license agreement.
Outlook, management commentary and risks
- Management estimated cash and expected Janssen research funding would support operating and capital expenditure requirements into 2022, subject to assumptions that could prove incorrect. The liquidity note separately says quarter-end cash is sufficient for at least 12 months; these are distinct statements in the filing.
- Management expects substantial increases in operating expenses as clinical development, manufacturing capacity, hiring and public-company costs expand. The company expects continued losses and may need additional capital; it has no assurance that financing will be available on acceptable terms.
- Janssen’s agreement covers three inherited retinal disease clinical candidates, with the company responsible for development and manufacturing and Janssen paying 100% of clinical and commercialization costs. MeiraGTx may receive 20% royalties and up to $340 million in milestones. Janssen may also opt into research candidates under separate terms.
- Pipeline updates: AAV-RPE65 Phase 1/2 data were described as positive, with safety and tolerability primary endpoints met and statistically significant improvements on several secondary endpoints; regulatory discussions were expected in the second half of 2019. AAV-CNGB3 enrollment was complete at 23 patients; AAV-RPGR was enrolling an extension study; AAV-GAD regulatory discussions were anticipated mid-2019; and AAV-hAQP1 continued enrolling, with a further trial anticipated in 2019.
- Key risks include clinical efficacy and safety uncertainty, evolving gene-therapy regulation, manufacturing scale-up and supply, patient enrollment, dependence on licensed intellectual property and collaborators, foreign-exchange exposure, and future financing needs. A 10% unfavorable currency movement was not expected to cause a significant increase in net loss. No material legal proceedings or subsequent events were reported. Management judged disclosure controls effective.
Important facts for investors to verify
- Reconcile the stated runway “into 2022” with the liquidity note’s “at least the next twelve months,” and assess the assumptions about spending and Janssen funding.
- Track Janssen performance-obligation revenue recognition, deferred revenue, research reimbursements and any exercised research options or achieved milestones.
- Review final, audited clinical data and regulatory feedback for AAV-RPE65 and the other lead programs; the reported Q1 clinical updates are not evidence of approval or commercial success.
- Monitor R&D and manufacturing cost growth, cash burn excluding upfront collaboration and financing proceeds, and the timing and terms of any additional capital raising.
- Assess the dilution and resale-registration provisions associated with the 2019 private placement, including potential liquidated damages if registration effectiveness is delayed.